{"title":"硫胺醇治疗有色皮肤患者黄褐斑：疗效和安全性的初步报告。","authors":"Rashmi Sarkar, Anjali Sahu, Vibhu Mendiratta, Sonali Langar","doi":"10.4103/idoj.idoj_1170_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Melasma poses significant therapeutic challenges, especially in patients with skin of color, due to the increased risk of post-inflammatory hyperpigmentation. Thiamidol, a novel topical tyrosinase inhibitor, has demonstrated potential efficacy with a favorable safety profile in treating hyperpigmentation disorders.</p><p><strong>Objective: </strong>This case series evaluates the efficacy and safety of Thiamidol in women of skin of color with melasma.</p><p><strong>Patients and methods: </strong>Ten Indian women with Fitzpatrick skin types III-V and melasma applied 0.2% Thiamidol twice daily for 12 weeks. Outcomes were measured using the modified Melasma Area and Severity Index (mMASI) and patient satisfaction scores.</p><p><strong>Results: </strong>The average reduction in mMASI was 34.4%, with patient satisfaction averaging 62%. Reported adverse effects were minimal and self-limiting.</p><p><strong>Limitations: </strong>A small sample size and the lack of a control group limit generalizability of the results. Future research should explore thiamidol's efficacy in combination therapies and assess its long-term benefits.</p><p><strong>Conclusion: </strong>Thiamidol is a promising and well-tolerated treatment for melasma in patients with skin of color.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"16 5","pages":"760-764"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419698/pdf/","citationCount":"0","resultStr":"{\"title\":\"Thiamidol in Melasma in Patients of Skin of Color: A Preliminary Report of Efficacy and Safety.\",\"authors\":\"Rashmi Sarkar, Anjali Sahu, Vibhu Mendiratta, Sonali Langar\",\"doi\":\"10.4103/idoj.idoj_1170_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Melasma poses significant therapeutic challenges, especially in patients with skin of color, due to the increased risk of post-inflammatory hyperpigmentation. Thiamidol, a novel topical tyrosinase inhibitor, has demonstrated potential efficacy with a favorable safety profile in treating hyperpigmentation disorders.</p><p><strong>Objective: </strong>This case series evaluates the efficacy and safety of Thiamidol in women of skin of color with melasma.</p><p><strong>Patients and methods: </strong>Ten Indian women with Fitzpatrick skin types III-V and melasma applied 0.2% Thiamidol twice daily for 12 weeks. Outcomes were measured using the modified Melasma Area and Severity Index (mMASI) and patient satisfaction scores.</p><p><strong>Results: </strong>The average reduction in mMASI was 34.4%, with patient satisfaction averaging 62%. Reported adverse effects were minimal and self-limiting.</p><p><strong>Limitations: </strong>A small sample size and the lack of a control group limit generalizability of the results. Future research should explore thiamidol's efficacy in combination therapies and assess its long-term benefits.</p><p><strong>Conclusion: </strong>Thiamidol is a promising and well-tolerated treatment for melasma in patients with skin of color.</p>\",\"PeriodicalId\":13335,\"journal\":{\"name\":\"Indian Dermatology Online Journal\",\"volume\":\"16 5\",\"pages\":\"760-764\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419698/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Dermatology Online Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/idoj.idoj_1170_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Dermatology Online Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/idoj.idoj_1170_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Thiamidol in Melasma in Patients of Skin of Color: A Preliminary Report of Efficacy and Safety.
Background: Melasma poses significant therapeutic challenges, especially in patients with skin of color, due to the increased risk of post-inflammatory hyperpigmentation. Thiamidol, a novel topical tyrosinase inhibitor, has demonstrated potential efficacy with a favorable safety profile in treating hyperpigmentation disorders.
Objective: This case series evaluates the efficacy and safety of Thiamidol in women of skin of color with melasma.
Patients and methods: Ten Indian women with Fitzpatrick skin types III-V and melasma applied 0.2% Thiamidol twice daily for 12 weeks. Outcomes were measured using the modified Melasma Area and Severity Index (mMASI) and patient satisfaction scores.
Results: The average reduction in mMASI was 34.4%, with patient satisfaction averaging 62%. Reported adverse effects were minimal and self-limiting.
Limitations: A small sample size and the lack of a control group limit generalizability of the results. Future research should explore thiamidol's efficacy in combination therapies and assess its long-term benefits.
Conclusion: Thiamidol is a promising and well-tolerated treatment for melasma in patients with skin of color.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
